Related Experiment Video
Updated: Jan 27, 2026

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab
Panagiota Economopoulou1, Vassiliki Kotoula2, Georgia-Angeliki Koliou3
1Second Department of Internal Medicine, Attikon University Hospital, 1 Rimini St 12462, Haidari, Athens, Greece.
Background:
Src, CDKN1B, and JAK2 play a crucial role in the coordination of cell signaling pathways. In the present study, we aim to investigate the prognostic significance of these biomarkers in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab (T).
Methods:
Formalin-fixed paraffin-embedded tumor tissue samples from 197 patients with HER2-positive MBC treated with T were retrospectively collected. All tissue samples were centrally assessed for ER, PgR, Ki67, HER2, and PTEN protein expression; EGFR gene amplification; PI3KCA mutational status; and tumor-infiltrating lympocytes density. Src, CDKN1B, and JAK2 mRNA expression was evaluated using quantitative reverse transcription-polymerase chain reaction.
Results:
Only 133 of the 197 patients (67.5%) were found to be HER2-positive by central assessment. CDKN1B mRNA expression was strongly correlated with Src (rho = 0.71) and JAK2 (rho = 0.54). In HER2-positive patients, low CDKN1B conferred higher risk for progression [hazard ratio (HR) = 1.58, 95% confidence interval (CI) 1.08-2.32, P = .018]. In HER2-negative patients, low Src was associated with longer survival (HR = 0.56, 95% CI 0.32-0.99, P = .045). Upon multivariate analyses, only low CDKN1B and JAK2 mRNA expression remained unfavorable factors for PFS in de novo and relapsed (R)-MBC patients, respectively (HR = 2.36, 95% CI 1.01-5.48, P = .046 and HR = 1.76, 95% CI 1.01-3.06, P = .047, respectively).
Conclusions:
Low CDKN1B and JAK2 mRNA expressions were unfavorable prognosticators in a cohort of T-treated MBC patients. Our results suggest that CDKN1B and JAK2, if validated, may serve as prognostic factors potentially implicated in T resistance, which seems to be associated with distinct pathways in de novo and R-MBC.
Insights
Low CDKN1B and JAK2 mRNA expression are unfavorable prognostic factors in metastatic breast cancer patients treated with trastuzumab. These biomarkers may predict trastuzumab resistance, suggesting distinct pathways in de novo and relapsed disease.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Src, CDKN1B, and JAK2 are key in cell signaling.
- Their prognostic significance in HER2-positive metastatic breast cancer (MBC) treated with trastuzumab (T) is investigated.
Purpose of the Study:
- To evaluate the prognostic value of Src, CDKN1B, and JAK2 in HER2-positive MBC patients receiving trastuzumab.
- To explore their potential role in trastuzumab resistance.
Main Methods:
- Retrospective analysis of 197 HER2-positive MBC patients treated with T.
- Assessment of protein expression (ER, PgR, Ki67, HER2, PTEN), EGFR amplification, PI3KCA mutations, and TILs.
- Quantification of Src, CDKN1B, and JAK2 mRNA expression via RT-qPCR.
Main Results:
- Low CDKN1B mRNA expression correlated with higher progression risk in HER2-positive patients (HR=1.58).
- Low Src was linked to longer survival in HER2-negative patients (HR=0.56).
- Low CDKN1B and JAK2 mRNA expression were unfavorable prognostic factors for progression-free survival in de novo and relapsed MBC, respectively.
Conclusions:
- Low CDKN1B and JAK2 mRNA expression are unfavorable prognosticators in trastuzumab-treated MBC.
- CDKN1B and JAK2 may serve as prognostic factors for trastuzumab resistance.
- Distinct pathways may be involved in trastuzumab resistance in de novo versus relapsed MBC.
Related Concept Videos
Impact of Groups on Groups
Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
Impact Loading
In cases of elastic deformation,...
Types of Impact
The coefficient of restitution is a metric for understanding the dynamics of impacts. It quantifies the ratio of relative velocity...
Impact: Problem Solving
By designating the launch point as the origin and utilizing kinematic equations, the vertical component of the projectile's velocity at the point of impact is...
Impact of Groups on Individuals

